Setting # 1
|
|
|
|
Product |
ImmuFact
IMP321 Monotherapy |
|
|
|
|
Therapeutic indications |
Metastatic Renal Cell
Carcinoma (MRCC) |
|
|
|
|
Approach |
IMP321 alone (high dose
for systemic exposure) |
|
|
|
|
Mechanism of action |
T cell immune response
stimulation as a monotherapy |
|
|
|
|
Development Phase |
Phase I/IIa |
|
|
|
|
Status of development
phase |
Completed |
|
|
|
|
Preclinical results |
Proof of concept in animal
models No toxicity |
|
|
|
|
Clinical results |
MRCC: 21 evaluable patients. |
|
|
IMP321 induced both
sustained CD8 T cell activation and an increase in the percentage of
long-lived effector-memory CD8 T cells in all
patients at doses above 6 mg. Tumor growth was reduced and progression-free
survival was better in those patients receiving higher doses (>6 mg) of
IMP321: 7 out of 8 evaluable patients treated at the higher doses
experienced stable disease at three months compared to only 3 out of
|
Setting # 2
|
|
|
|
Product |
ImmuFact
IMP321 Chemo-Immunotherapy |
|
|
|
|
Therapeutic indications |
Metastatic breast cancer
(MBC) in the EU Advanced pancreatic cancer
in the |
|
|
|
|
Approach |
Chemotherapy followed by
IMP321 alone (high dose for systemic exposure) |
|
|
|
|
Mechanism of action |
T cell immune response
stimulation in patients receiving first-line chemotherapy |
|
|
|
|
Development Phase |
Phase I/IIa |
|
|
|
|
Status of development
phase |
MBC: completed (paclitaxel + 12 IMP321 Advanced pancreatic cancer:
in progress (gemcitabine + 12 IMP321 |
|
|
|
|
Preclinical results |
Proof of concept in animal
models No toxicity |
|
|
|
|
Clinical results |
MBC: 30
evaluable patients. IMP321 induced both a
sustained increase in the number and activation of APC (monocytes
and dendritic cells) and an increase in the
percentage of NK and long-lived cytotoxic effector-memory CD8 T cells. Clinical benefit was observed for 90 % of
patients with only 3 progressors at 6 months. Also, the objective tumor
response rate of 50 % compared favorably to the 25
% rate reported in the historical control group (p=0.005).) |
|
|
Pancreatic cancer: 30 pt phase I/IIa to show safety and
immune response. |
Setting # 3
|
|
|
|
Product |
ImmuFact
IMP321 Adjuvant |
|
|
|
|
Therapeutic indications |
Post-surgery melanoma Metastatic melanoma Ovarian cancer |
|
|
|
|
Approach |
Low dose IMP321 mixed with
antigen |
|
|
|
|
Mechanism of action |
T cell immune response
stimulation as an adjuvant for therapeutic vaccines |
|
|
|
|
Development Phase |
Phase I/IIa |
|
|
|
|
Status of development
phase |
Post-surgery melanoma: completed Metastatic melanoma: in progress |
|
|
|
|
Preclinical results |
Proof of concept in
animals models No toxicity |
|
|
|
|
Clinical results |
|
|
|
|
Setting # 4
|
|
|
|
Product |
ImmuTune
IMP701 Antagonist Antibody |
|
|
|
|
Therapeutic indications |
Cancer Chronic infectious
diseases |
|
|
|
|
Approach |
Monoclonal antibody |
|
|
|
|
Mechanism of action |
Blockade of LAG-3-mediated
immune down-regulation |
|
|
|
|
Development Phase |
Preclinical |
|
|
|
|
Status of development
phase |
Optimisation |
|
|
|
Setting # 5
|
|
|
|
Product |
ImmuTune IMP731
Depleting Antibody |
|
|
|
|
Therapeutic indications |
Autoimmune diseases and
transplantation |
|
|
|
|
Approach |
Monoclonal antibody (chimeric) |
|
|
|
|
Mechanism of action |
Killing activated Effector-Memory LAG-3+ T cells |
|
|
|
|
Development Phase |
Clinical |
|
|
|
|
Status of development
phase |
Moving into clinical
production and then phase I |
|
|
|